{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:38:33Z","timestamp":1781019513600,"version":"3.54.1"},"reference-count":41,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["568985"],"award-info":[{"award-number":["568985"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008810","name":"New South Wales Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The National Centre in HIV Social Research"},{"name":"The Kirby Institute"},{"DOI":"10.13039\/501100001027","name":"Australian Government Department of Health and Ageing","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001027","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Provision of hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) assessment and treatment via opioid substitution treatment (<jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content>) clinics has been posed as an effective means of engaging populations with high <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalence. This study explores <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> client and health professional reports concerning barriers and facilitators affecting the delivery and uptake of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> care and treatment within <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> settings. In\u2010depth interviews were conducted with 57 clients, 16 staff from four <jats:styled-content style=\"fixed-case\">NSW<\/jats:styled-content> clinics participating in the Australian <jats:styled-content style=\"fixed-case\">ETHOS<\/jats:styled-content> study and three peer workers. Client participants included those who had not had <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> assessment; those who had <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> assessment only; and those who were awaiting or undertaking <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment. A clear difference in decisions about <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment emerged between participant groups. For those who have not been assessed, barriers to engaging with <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> care included the perception that they were physically well, were not experiencing <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> symptoms, had other life priorities and were concerned about the side effects and tolerability of treatment. Those who had engaged with care expressed motivations stemming from seeing friends becoming unwell, wanting to live longer and hearing positive stories of treatment. For those interested in <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment, issues related to both provider and setting were important, such as presence of an engaged clinician, an accessible treatment pathway and availability of support. In this integrated care model, some barriers to <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> care and treatment (particularly those relating to health provider and the system) are minimized. In this setting, <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatment remained an unattractive option for a significant number of clients. Providing ways for those without <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> symptoms to be assessed for liver damage may be important to open up alternative conversations about <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> care. Further, the importance of a changing discourse of treatment is apparent from these data and could be enhanced by peer communication that provides information about successful treatment experiences.<\/jats:p>","DOI":"10.1111\/jvh.12183","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T05:47:01Z","timestamp":1386049621000},"page":"560-567","source":"Crossref","is-referenced-by-count":52,"title":["Barriers and facilitators for assessment and treatment of hepatitis <scp>C<\/scp> virus infection in the opioid substitution treatment setting: insights from the <scp>ETHOS<\/scp> study"],"prefix":"10.1111","volume":"21","author":[{"given":"C.","family":"Treloar","sequence":"first","affiliation":[{"name":"National Centre in HIV Social Research The University of New South Wales Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rance","sequence":"additional","affiliation":[{"name":"National Centre in HIV Social Research The University of New South Wales Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Kirby Institute The University of New South Wales Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grebely","sequence":"additional","affiliation":[{"name":"Kirby Institute The University of New South Wales Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1297922"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.021"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23220"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099150"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01080.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-007-9083-3"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12129"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32834bcb36"},{"key":"e_1_2_7_11_1","volume-title":"Barriers and Facilitators to Hepatitis C Treatment for People Who Inject Drugs: A Qualitative Study","author":"Harris M","year":"2012"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0161.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02706.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit271"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1007"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/600304"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000104884"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3181add3de"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2008.09.009"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2011.10.003"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01250.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit305"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2010.0142"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01370.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/427446"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jana.2009.07.009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1057\/9780230582569"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.064"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13698570500108693"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2007.02.003"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10410230802676771"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.133.4.673"},{"key":"e_1_2_7_34_1","volume-title":"The Hepatitis C Treatment Pipeline Report","author":"Swan T","year":"2011"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2007.01.010"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32832a8c4c"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01648.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.08.007"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2012.00502.x"},{"issue":"2","key":"e_1_2_7_40_1","first-page":"S135","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Geert Robaeys G","year":"2013","journal-title":"Clin Infect Dis"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01050.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03246.x"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12183","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:52:01Z","timestamp":1696207921000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/jvh.12183"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12183","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,3]]}}}